Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPO-Vir Z30 FDC vs liquid formulations in HIV-infected children
NCT00672412Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2008
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GPO-VIR Z30 in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Oct 2008; status: completed.
02
Drugs
GPO-VIR Z30
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00672412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00672412.